MAB

(redirected from monoclonal antibody)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.

MAB

Master Air Waybill

A document describing goods to be transported by multiple airlines, usually internationally. The first airline issues a waybill to prove that the goods have been received and are ready for transport.
Mentioned in ?
References in periodicals archive ?
A team led by Lueienne Chatenoud of Hopital Necker in Paris developed a different CD3-targeting monoclonal antibody that prevented diabetes in mice.
The researchers subsequently modified that monoclonal antibody into the experimental drug ChAglyCD3, which is safer for people.
Chapter 2 - Trends in cancer monoclonal antibody dealmaking
Bigpharma cancer monoclonal antibody dealmaking activity
We expect significant opportunities for further commercial growth from 2009 to 2024, as shown in our new report, Monoclonal Antibody Therapeutics 2009-2024.
Table 2: Leading Players in the Worldwide Monoclonal Antibody Therapy Market (2005): Percentage Breakdown of Sales for Genentech/Roche, J & J/Schering Plough, Abbott Laboratories, MedImmune, ImClone/BMS, and Eli Lilly (includes corresponding Graph/Chart) II-5
This report assesses the overall monoclonal antibody market, as part of the wider protein therapeutics industry.
Seattle Genetics and its collaborators presented preclinical data on SGN-70, a humanized monoclonal antibody that targets the CD70 antigen, which is expressed in many types of hematologic malignancies.
As the exclusive marketing and distribution partner for Rabies monoclonal antibody, Akorn will receive 40% of the revenues from product sales in North America and 50% of the revenues from product sales in Central and South America.
The Future of Monoclonal Antibody Therapeutics: Innovation in antibody engineering, key growth strategies and forecasts to 2011, is a unique report that combines up-to-date analysis of the current antibodies market with detailed insights into therapeutic, technology, discovery and drug delivery trends set to shape the market in the next 5 years and beyond.
XOMA has royalty interests in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc.

Full browser ?